A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
Status:
Completed
Trial end date:
2020-12-28
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn about the side effects of LY3437943 when given to
participants with type 2 diabetes. Blood tests will be performed to investigate how the body
processes the study drug and how the study drug affects the body. Each enrolled participant
will receive injections of LY3437943, dulaglutide, or placebo given just under the skin. For
each participant, the study will last up to about 5 months and will include 16 visits to the
study center.